Related Articles
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer
Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR‑T790M mutant lung cancer
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation
Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR